Devinder Gill

12.4k total citations · 2 hit papers
145 papers, 5.4k citations indexed

About

Devinder Gill is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Devinder Gill has authored 145 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Pathology and Forensic Medicine, 52 papers in Genetics and 42 papers in Oncology. Recurrent topics in Devinder Gill's work include Lymphoma Diagnosis and Treatment (62 papers), Chronic Lymphocytic Leukemia Research (48 papers) and Viral-associated cancers and disorders (18 papers). Devinder Gill is often cited by papers focused on Lymphoma Diagnosis and Treatment (62 papers), Chronic Lymphocytic Leukemia Research (48 papers) and Viral-associated cancers and disorders (18 papers). Devinder Gill collaborates with scholars based in Australia, United Kingdom and United States. Devinder Gill's co-authors include Marek Trněný, Craig H. Moskowitz, Nicolas Mounier, Norbert Schmitz, Christian Gisselbrecht, Ofer Shpilberg, Josette Brière, David C. Linch, Nicolas Ketterer and Dávid Ma and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Devinder Gill

142 papers receiving 5.2k citations

Hit Papers

Salvage Regimens With Aut... 2010 2026 2015 2020 2010 2018 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
    2010 1.1k citations Christian Gisselbrecht, Bertram Glaß et al. Journal of Clinical Oncology profile →
  2. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
    2018 380 citations Devinder Gill et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Devinder Gill 2.7k 2.5k 1.4k 1.2k 946 145 5.4k
Swaminathan P. Iyer 1.9k 0.7× 2.1k 0.8× 1.4k 1.0× 1.4k 1.2× 2.1k 2.3× 286 7.4k
Martin Zimmermann 1.7k 0.6× 1.3k 0.5× 795 0.6× 355 0.3× 1.3k 1.4× 151 5.6k
John M. Pagel 2.7k 1.0× 3.1k 1.3× 2.8k 2.0× 1.8k 1.6× 2.7k 2.9× 286 9.3k
Paolo Corradini 3.7k 1.4× 4.5k 1.8× 2.6k 1.8× 2.5k 2.2× 2.9k 3.1× 411 11.0k
Gerhard Zugmaier 1.1k 0.4× 4.6k 1.9× 449 0.3× 1.6k 1.4× 2.0k 2.2× 146 7.4k
Michael Kneba 4.1k 1.5× 2.3k 0.9× 3.5k 2.4× 1.7k 1.5× 991 1.0× 216 8.1k
Christian Buske 2.5k 0.9× 2.2k 0.9× 3.2k 2.2× 1.5k 1.3× 3.7k 3.9× 256 9.3k
Daan Dierickx 1.4k 0.5× 1.9k 0.8× 432 0.3× 587 0.5× 610 0.6× 152 3.8k
Malik E. Juweid 4.7k 1.7× 2.7k 1.1× 984 0.7× 622 0.5× 737 0.8× 126 8.1k
Kengo Takeuchi 3.2k 1.2× 6.5k 2.6× 959 0.7× 1.1k 1.0× 3.7k 3.9× 339 12.0k

Countries citing papers authored by Devinder Gill

Since Specialization
Citations

This map shows the geographic impact of Devinder Gill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Devinder Gill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Devinder Gill more than expected).

Fields of papers citing papers by Devinder Gill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Devinder Gill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Devinder Gill. The network helps show where Devinder Gill may publish in the future.

Co-authorship network of co-authors of Devinder Gill

This figure shows the co-authorship network connecting the top 25 collaborators of Devinder Gill. A scholar is included among the top collaborators of Devinder Gill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Devinder Gill. Devinder Gill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Burgess, Melinda, Colm Keane, Joshua W.D. Tobin, et al.. (2022). Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic Leukemia. Acta Haematologica. 146(2). 166–171. 1 indexed citations
2.
Heyer, Erin E., Ira W. Deveson, Christina Selinger, et al.. (2019). Diagnosis of fusion genes using targeted RNA sequencing. Nature Communications. 10(1). 1388–1388. 131 indexed citations
3.
Tobin, Joshua W.D., Jane Royle, Robert M. Mason, et al.. (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. Blood. 130. 5338–5338. 4 indexed citations
4.
Mulligan, Stephen P., Karin Karlsson, Viggo Jønsson, et al.. (2014). Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia. Leukemia & lymphoma. 55(12). 2769–2777. 13 indexed citations
5.
Burgess, Melinda, Devinder Gill, Richa Singhania, et al.. (2013). CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 19(20). 5675–5685. 29 indexed citations
6.
Jones, Kimberley, Frank Vari, Colm Keane, et al.. (2012). Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma. Clinical Cancer Research. 19(3). 731–742. 83 indexed citations
7.
Gisselbrecht, Christian, Bertram Glaß, Nicolas Mounier, et al.. (2010). Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era. Journal of Clinical Oncology. 28(27). 4184–4190. 1117 indexed citations breakdown →
8.
Rieger, Michael A., Anders Österborg, Ruth Pettengell, et al.. (2010). Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Annals of Oncology. 22(3). 664–670. 139 indexed citations
9.
10.
Keane, Colm & Devinder Gill. (2008). Multi‐organ involvement with crystal‐storing histiocytosis. British Journal of Haematology. 141(6). 750–750. 7 indexed citations
11.
Johnson, David W., Mark Jones, Devinder Gill, et al.. (2007). Immunosuppression (IST) Can Be Safely Ceased during Chemotherapy for PTLD in Renal Transplant Patients. Queensland's institutional digital repository (The University of Queensland). 1 indexed citations
12.
Basak, Amit, Andre Raw, Ali Al‐Hakim, et al.. (2006). Pharmaceutical impurities: Regulatory perspective for Abbreviated New Drug Applications☆☆☆. Advanced Drug Delivery Reviews. 59(1). 64–72. 52 indexed citations
13.
Gandhi, Maher K., Eleanore Lambley, Paula Marlton, et al.. (2005). LAG-3 expressing lymphocytes suppress EBV latent membrane protein-specific T cell function in Hodgkins lymphoma patients. Annals of Oncology. 16. 84–85. 1 indexed citations
14.
Spencer, Andrew, Michael Seldon, Ralph Cobcroft, et al.. (2004). Induction with oral chemotherapy (CID) followed by early autologous stem cell transplantation for de novo multiple myeloma patients. The Hematology Journal. 5(3). 216–221. 9 indexed citations
15.
Tey, Siok‐Keen, Ralph Cobcroft, Karen Grimmett, et al.. (2004). A simplified endogenous erythroid colony assay for the investigation of polycythaemia. Clinical & Laboratory Haematology. 26(2). 115–121. 3 indexed citations
16.
Herzig, Karen A., Helen G. Juffs, Allison Brown, et al.. (2003). A single-centre experience of post-renal transplant lymphoproliferative disorder. Transplant International. 16(7). 529–536. 32 indexed citations
17.
Tey, Siok‐Keen, et al.. (2002). Incidence and nature of CD20 negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: A retrospective review.. Blood. 100(11). 17 indexed citations
18.
19.
Grivas, C., et al.. (1998). Growth and performance of pulsed laser deposited indium oxide thin-film holographic recorders. ePrints Soton (University of Southampton). 6 indexed citations
20.
Cobcroft, Ralph, et al.. (1994). Fluctuating symptomatic cryofibrinogenaemia in a patient with left atrial myxoma. British Journal of Haematology. 88(1). 213–214. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Swaminathan P. Iyer Breakdown of academic impact, for papers by Martin Zimmermann Breakdown of academic impact, for papers by John M. Pagel Breakdown of academic impact, for papers by Paolo Corradini Breakdown of academic impact, for papers by Gerhard Zugmaier Breakdown of academic impact, for papers by Michael Kneba Breakdown of academic impact, for papers by Christian Buske Breakdown of academic impact, for papers by Daan Dierickx Breakdown of academic impact, for papers by Malik E. Juweid Breakdown of academic impact, for papers by Kengo Takeuchi
Rankless by CCL
2026